MR-NIRF Fe3O4-Cy5.5-NGR bimodel contrast agents ovarian cancer cells

doi:10.3969/j.issn.1006-7795.2018.01.016

Abstract

Abstract: Objective To synthesize magnetic resonance (MR) and near-infrared fluorescence (NIR) bimodel contrast agents Fe₃O₄-Cy5.5-NGR and verify the targeting ability in virto on ES-2 ovarian cancer cells.Methods Fe₃O₄-Cy5.5-NGR as experimental group and Fe₃O₄-Cy5.5 as control group, physical and chemical properties with transmission electron microscope (TEM), infrared spectroscopy (FITR) and ultraviolet spectrophotometer (UV-general physical and chemical properties 2600). ES-2 human ovarian cancer clear cell subculture lines for CD13 immunohistochemical staining and the expression of CD13 on cell surface. Co-incubate contrasting agents and ES-2 cells cytotoxicity and specific binding ability under flow cytometer. susceptibility of Fe₃O₄-Cy5.5-NGR and Fe₃O₄-Cy5.5 as magnetic nanoparticles on 7.0TMR.Results Fe₃O₄-Cy5.5-NGR is sharper than Fe₃O₄-Cy5.5, the mean diameter is (8.93 ±0.773)nm for NGR-connected agent and (7.48 ±0.695) nm for the other. Excitation wavelength for both agents is 628.0 nm and reflected wavelength is 675.2 nm; Fe₃O₄-Cy5.5-NGR and Fe₃O₄-Cy5.5 got specific peaks at 2 882 cm^-1 and 1 632 cm^-1; NGR-connected agents had another peaks at 841 cm^-1. No cytotoxicity displayed after co-incubate under CCK-8 text. High fluorescence on cell surface and slightly at the location of nucleus and fiber matrix with CD13 immunohistochemical staining. The values of r2 are 155.49 mmol·L^-1·s^-1, 180.74 mmol·L^-1·s^-1 for Fe₃O₄-Cy5.5-NGR Fe₃O₄-Cy5.5 seperatly. The fluorescence intensity of Fe₃O₄-Cy5.5-NGR is relatively high than Fe₃O₄-Cy5.5 in different concentrations(40, 80 and 160 μmol), the number were 3.1, 1.65 and 1.26 times, respectively.Conclusion Fe₃O₄-Cy5.5-NGR performed well on targeting ability as MRI-NIRF bimodal contrast agent in vitro on ES-2 cells, which may use in ovarian cancer xenografts on nude mice experiments.

Key words: ovarian cancer, near infrared fluorescence, targeting ability

CLC Number:

R737.31

Zhang Zixin, Meng Ying, Liang Yuting. MR-NIRF Fe₃O₄-Cy5.5-NGR bimodel contrast agents ovarian cancer cells[J]. Journal of Capital Medical University, 2018, 39(1): 84-91.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.01.016

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I1/84

References

[1] Jayson G C, Kohn E C, Kitchener H C, et al. Ovarian cancer[J]. Lancet, 2014, 384(9951):1376-1388.
[2] Raave R, de Vries R B, Massuger L F, et al. Drug delivery systems for ovarian cancer treatment:a systematic review and meta-analysis of animal studies[J]. Peer J, 2015, 3:e1489.
[3] Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum:abridged republication of guidelines from the international federation of gynecology and obstetrics (FIGO)[J]. Obstet Gynecol, 2015, 126(1):171-174.
[4] Shao M, Hollar S, Chambliss D, et al. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer[J]. Mol Cancer Ther, 2012, 11(7):1576-1586.
[5] Cui S X, Qu X J, Gao Z H, et al. Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells[J]. Cancer Lett, 2010, 292(2):153-162.
[6] Pereira F E, Cronin C, Ghosh M, et al. CD13 is essential for inflammatory trafficking and infarct healing following permanent coronary artery occlusion in mice[J]. Cardiovasc Res, 2013, 100(1):74-83.
[7] Li G, Xing Y, Wang J, et al. Near-infrared fluorescence imaging of CD13 receptor expression using a novel Cy5.5-labeled dimeric NGR peptide[J]. Amino Acids, 2014, 46(6):1547-1556.
[8] Craddock K J, Chen Y, Brandwein J M, et al. CD13 expression is an independent adverse prognostic factor in adults with Philadelphia chromosome negative B cell acute lymphoblastic leukemia[J]. Leukemia Res, 2013, 37(7):759-764.
[9] Zhang Z, Hu Y, Yang J, et al. Facile synthesis of folic acid-modified iron oxide nanoparticles for targeted MR imaging in pulmonary tumor xenografts[J]. Mol Imaging Biol, 2016,18(4):569-578.
[10] Savla R, Garbuzenko O B, Chen S, et al. Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy[J]. Pharm Res, 2014, 31(12):3487-3502.
[11] Onoe S, Temma T, Kanazaki K, et al. Development of photostabilized asymmetrical cyanine dyes for in vivo photoacoustic imaging of tumors[J]. J Biomed Opt, 2015, 20(9):096006.
[12] Luo S, Zhang E, Su Y, et al. A review of NIR dyes in cancer targeting and imaging[J]. Biomaterials, 2011, 32(29):7127-7138.
[13] Chen N, Shao C, Li S, et al. Cy5.5 conjugated MnO nanoparticles for magnetic resonance/near-infrared fluorescence dual-modal imaging of brain gliomas[J]. J Colloid Interface Sci, 2015, 457:27-34.
[14] Xiao N, Gu W, Wang H, et al. T1-T2 dual-modal MRI of brain gliomas using PEGylated Gd-doped iron oxide nanoparticles[J]. J Colloid Interface Sci, 2014, 417:159-165.
[15] Wang Y X, Hussain S M, Krestin G P. Superparamagnetic iron oxide contrast agents:physicochemical characteristics and applications in MR imaging[J]. Eur Radiol, 2001, 11(11):2319-2331.

MR-NIRF Fe₃O₄-Cy5.5-NGR bimodel contrast agents ovarian cancer cells

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	Wang Wenwen, Cai Yu, Jia Shuangshuang, Zhai Jianjun. Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer [J]. Journal of Capital Medical University, 2023, 44(1): 143-147.
[2]	Liu Qun, Li Lina, Liu Jian, Miao Jinwei. SOX4 mediates TGF-β1 induced epithelial-mesenchymal transition to promote invasion and metastasis of ovarian cancer [J]. Journal of Capital Medical University, 2022, 43(3): 336-342.
[3]	Liu Chen, Wu Long, Jiang Hongchuan, Li Jie, Liu Jun, Wang Shuzhen. Risk factor of second primary gynecological malignancy among women with breast cancer surgery [J]. Journal of Capital Medical University, 2017, 38(1): 92-96.
[4]	Li Jinfeng;Zhang Zhenyu;Wang Shuzhen;Liu Jinwei. The Anti-tumor Immunity and Cultivation of the Fused Cells of Ovarian Cancer and Dendritic Cells Derived from Cord Blood——An In-vitro Study [J]. Journal of Capital Medical University, 2007, 28(5): 604-608.
[5]	Wei Wei;Shen Keng;Zhao Lihong;Cao Yang. Establishment of Fisher344 Rat Animal Model of Epithelial Ovarian Cancer [J]. Journal of Capital Medical University, 2007, 28(1): 52-55.
[6]	Lin Yugeng;Zhang Zhenyu;Wang Lisheng;Wu Bin. Effects of Wild-type p53,GM-CSF and B7-1 Genes Transfer on Proliferation of Ovarian Cancer Cell Line SKOV-3 [J]. Journal of Capital Medical University, 2005, 26(5): 588-592.